{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.52","upperLimit":"46.92","value":"33.22"},{"groupId":"OG001","lowerLimit":"30.26","upperLimit":"50.00","value":"38.90"},{"groupId":"OG002","lowerLimit":"29.33","upperLimit":"49.22","value":"37.99"},{"groupId":"OG003","lowerLimit":"31.85","upperLimit":"52.47","value":"40.88"},{"groupId":"OG004","lowerLimit":"27.14","upperLimit":"295.1","value":"89.49"},{"comment":"Data could not be calculated because there were no subjects evaluated for this arm at the specified time point.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"24.95","upperLimit":"41.36","value":"32.12"},{"groupId":"OG007","lowerLimit":"27.16","upperLimit":"39.50","value":"32.75"},{"groupId":"OG008","lowerLimit":"23.41","upperLimit":"40.41","value":"30.75"},{"groupId":"OG009","lowerLimit":"41.61","upperLimit":"69.62","value":"53.94"}]}],"title":"Day 1 (n=6, 10, 26, 13, 3, 0, 22, 22, 14, 13)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.59","upperLimit":"34.10","value":"23.06"},{"groupId":"OG001","lowerLimit":"27.63","upperLimit":"40.13","value":"33.30"},{"groupId":"OG002","lowerLimit":"26.82","upperLimit":"51.33","value":"37.11"},{"groupId":"OG003","lowerLimit":"30.19","upperLimit":"41.23","value":"35.28"},{"groupId":"OG004","lowerLimit":"15.03","upperLimit":"225.6","value":"58.22"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"22.54","upperLimit":"35.07","value":"28.11"},{"groupId":"OG007","lowerLimit":"25.85","upperLimit":"38.94","value":"31.73"},{"groupId":"OG008","lowerLimit":"22.59","upperLimit":"40.38","value":"30.20"},{"groupId":"OG009","lowerLimit":"30.17","upperLimit":"52.52","value":"39.81"}]}],"title":"Day 15 (n=6, 9, 15, 9, 3, 1, 16, 17, 10, 13)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"description":"The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the Dose with area under the plasma concentration time curve from time zero to infinity (AUC0 inf)=Dose/AUC0- inf.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 15 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG000","title":"Pimasertib (MSC1936369B) 15mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG001","title":"Pimasertib (MSC1936369B) 30mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG002","title":"Pimasertib (MSC1936369B) 60mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG003","title":"Pimasertib (MSC1936369B) 90mg"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 45 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG004","title":"Pimasertib (MSC1936369B) 45mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG005","title":"Pimasertib (MSC1936369B) 60mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: Pimasertib 60mg Once Daily"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set. Here \"N\" signifies number of subjects evaluable for this outcome measure and \"n\" signifies the number of subjects evaluable at the specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Total Body Clearance (CL/f) of Pimasertib (MSC1936369B)","type":"SECONDARY","unitOfMeasure":"litre per hour (L/hr)"}